13 mai 2022 – The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) started evaluating an application to extend the use of Spikevax to include children from 6 months to 5 years of age. Spikevax is a vaccine for preventing Covid-19 in people aged 6 years and older. Spikevax contains elasomeran, a messenger RNA (mRNA) molecule with instructions for producing a protein from SARS-CoV-2, the virus that causes Covid-19. Spikevax is not currently authorised for children below 6 years of age.

For more information, see here.